A global clinical trial involving The Hospital for Sick Children (SickKids) has found that mavacamten—a heart medication ...

Significantly less cancer-related cognitive impairment, mental fatigue after chemotherapy ...

The FDA has approved a drug for patients who are 12 and older with classical Hodgkin lymphoma based on the results of a ...

Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company” ...

The results run counter to ABYSS but align with other data showing beta-blockers shouldn’t continue indefinitely after MI.

In stable patients without heart failure, discontinuing beta-blockers 1 year after a heart attack was noninferior to ...

Whole-blood transfusion has recently gained favor in the management of severe hemorrhage; however, data from large clinical trials evaluating its clinical effectiveness and safety are lacking. We ...

In what is believed to be the first randomized placebo-controlled trial of its kind, patients with a chronic total blockage ...

Adding tirzepatide to ixekizumab significantly improved primary and key secondary outcomes ...

Emboline, Inc., a privately held medical technology company developing embolic protection solutions for structural heart procedures, today announced positive results from its pivotal PROTECT H2H ...

Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, ...